|
Cubist Pharmaceuticals is a U.S. biopharmaceutical company with activities spanning from research and development to commercialization of pharmaceutical products. Its main products target pathogens like MRSA. Cubist is one of the few firms that have continued to research in antibiotics while larger pharmaceutical companies have abandoned such research. The company employs 638 people, with 370 in their headquarters in Lexington, MA.〔(【引用サイトリンク】 work=2009 Annual Report )〕 As of 2011, the company’s headquarters are under expansion and is expected to occupy in Lexington, MA. On 8 December 2014, Merck & Co. acquired Cubist for $102 per share in cash (US$8.4BN) as entree to the market for drugs that can combat superbugs.〔(Merck to take on superbugs with Cubist Pharma buy ). Reuters, 9 December 2014〕 ==History== Cubist appeared on Fortune 2010’s List of fastest growing companies, and was named to the 2010 Deloitte Technology Fast 500. In 2006 it had the 19th highest sales among American based biotechnology companies. In 2011, the company acquired Adolor, maker of a drug for treatment of constipation.〔 Cubist has an ambitious growth plan laid out for the 2012-2017 quinquennium. Under this plan, the company should reach 2B dollars in sales and have 4 new drugs in late stage development by 2017. As a part of this plan, sales of its flagship drug Cubicin are expected to grow to more than 1B dollars per year. In July 2013, Cubist Pharmaceuticals agreed to purchase Trius Therapeutics and Optimer Pharmaceuticals for around $1.6 billion. In October 2014, Cubist announced a new, CEO Robert J. Perez, to take leadership on January 1, 2015. In January 2015 Cubist Pharmaceuticals became a wholly owned subsidiary of Merck & Co. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Cubist Pharmaceuticals」の詳細全文を読む スポンサード リンク
|